The development of novel adenovirus vectors and application for treatment, prevention, and diagnosis of diseases
Project/Area Number |
26242048
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Biomedical engineering/Biomaterial science and engineering
|
Research Institution | Osaka University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
SAKURAI FUMINORI 大阪大学, 大学院・薬学研究科, 准教授 (70370939)
TACHIBANA MASASHI 大阪大学, 大学院・薬学研究科, 助教 (80513449)
|
Project Period (FY) |
2014-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥33,150,000 (Direct Cost: ¥25,500,000、Indirect Cost: ¥7,650,000)
Fiscal Year 2016: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2015: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2014: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
Keywords | ウイルス / 遺伝子 / 癌 / 免疫学 / バイオテクノロジー |
Outline of Final Research Achievements |
In this study, we developed several types of novel recombinant adenoviruses (Ad) for the treatment, prevention, and diagnosis of diseases. We developed Cas9-expressing adenovirus vector for genome editing. We analyzed the mechanism how intramuscular vaccination of an adenovirus vector promotes the induction of antigen-specific gut-mucosal CTLs. We also developed a novel detection system of circulating tumor cells using a green fluorescence protein-expressing conditionally replicating adenovirus.
|
Report
(4 results)
Research Products
(57 results)
-
-
-
-
[Journal Article] TANK-binding kinase 1-dependent or -independent signaling elicits the cell-type-specific innate immune responses induced by the adenovirus vector.2016
Author(s)
Tsuzuki S, Tachibana M, Hemmi M, Yamaguchi T, Shoji M, Sakurai F, Kobiyama K, Kawabata K, Ishii KJ, Akira S, Mizuguchi H.
-
Journal Title
International Immunology
Volume: 28
Pages: 105-115
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-